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specific immunity. As a result, the infiltration of tumorsJohn A. Sogn*
by these cells is not necessarily an indicator of a specificCancer Immunology Branch
immune reaction, and it cannot be assumed to be aDivision of Cancer Biology
favorable indicator for either the untreated clinicalNational Cancer Institute
course or the applicability of immunotherapy. Cells ofNational Institutes of Health
the immune system are sources of growth factors, oxi-Rockville, MD 20892±7388
dative products, and regulators of angiogenesis, and
they frequently appear to facilitate tumor growth. For
example, the aggressive growth of some variants ofThe goal of this review is to summarize where the field
ultraviolet light (UV)-induced tumors has been shown toof tumor immunology is today and to emphasize the
require granulocytes (Pekarek et al., 1995). Mast cellsintimate, two-way interactions that exist between tumor
can stimulate cancer growth under some conditionsimmunology and basic immunology. Tumor immunology
(Dimitriadou and Koutsilieris, 1997). Oxidative productslies at the intersection of two large, complex, and some-
like nitric oxide can serve as mutagens and facilitatewhat inbred disciplines: cancer research and immunol-
tumor growth and metastasis, in addition to killing tumorogy. It is perhaps best thought of as two fields: the use of
cells (Lala, 1998). Macrophages play several critical rolescancer as a model system in which to test immunologic
in tumor angiogenesis, including conversion of plasmin-principles, and the use of immunology as a tool to under-
ogen to angiostatin (Dong et al., 1997). Immune systemstand and treat cancer.
enhancement of tumor growth is especially common inThe ultimate measure of immunological progress is
hematopoietic tumors, where normal physiologic net-how well basic concepts can be integrated, synthesized,
works of cytokines and cell surface interactions become
and applied to real problems like cancer, autoimmunity,
driving forces in tumor growth (Umansky et al., 1996).
and infectious diseases. By this measure, immunology Finally, the lymphocyte-specific genomic instability in-
remains in its infancy. Much of tumor immunology is herent in antibody and T cell receptor (TCR) gene re-
intended to probe the limits of current immunologic con- arrangements is a factor in the majority of lymphoid
cepts by experiments in murine cancer models. Success malignancies (Kirsch and Lista, 1997). All of these as-
is measured by the extent to which the concepts are pects of tumor±immune system interaction are under-
tested and refined and not by their impact on human studied and insufficiently acknowledged in tumor immu-
disease, although there is a reductionist bias that this nology studies.
will be the ultimate result. However, the normal immune system can also effec-
Immunotherapy, especially T cell±directed immuno- tively prevent or limit tumor growth in some cases. Im-
therapy, dominates the current applications of immunol- munological surveillance clearly exists for virally derived
ogy to the understanding and treatment of cancer. Stud- tumors and nonmelanoma skin cancers (Klein, 1975).
ies in this field have investigated the role that cells and Beyond this, immunological surveillance was discounted
secreted products of the immune system play in creating for many years, but it has recently enjoyed a mild resur-
an environment either conducive or hostile to malignant gence on the basis of solid data. There is statistical
transformation, early tumor growth, and angiogenesis. evidence that it can extend to some of the other common
Some immunotherapy efforts are molecularly defined solid tumors (Birkeland et al., 1995). Recent evidence
has been presented for a direct role of interferon gammaand relate to current immunologic concepts, and others
(IFNg) in a form of immune surveillance (Kaplan et al.,are more empirical. While immunotherapy has yet to
1998), and TCR Vg1.1 cells in mice appear to reactexperience striking success, some immune-based ther-
spontaneously against acute T cell leukemias (Pen-apies are already having an impact on cancer treatment.
ninger et al., 1995). Statistical evidence exists for selec-
tion against lung cancers bearing p53 mutations pre-State of the Field: Basic Principles
dicted to be strongly antigenic (Wiedenfeld et al., 1994).The basic principles that underlie contemporary tumor
It is now widely accepted that few spontaneous tu-immunology are simple but have evolved considerably
mors are immunogenic, but most, if not all, are antigenic.in the past decade: (1) the normal immune system is
A substantial number of T cell±defined tumor antigensrarely a significant barrier to tumor growth, although
of various types have been isolated from rodent andlymphocytes play both positive and negative roles in
human tumors (Van den Eynde and van der Bruggen,tumor growth and development; (2) tumors are anti-
1997). All of the early studies concentrated on antigensgenic; and (3) manipulation of the immune system can
recognized by CD81 T cells, but work has recently beenlead to complete tumor eradication. The first two are
extended to antigens recognized by CD41 T cells. In
well established, but the third has been proven to date
most cases, the T cells used to identify the antigen were
only for a few special cases. tumor-infiltrating lymphocytes (TILs) from a patient or
Although it is clear that ªimmunological surveillanceº an experimental animal with a progressive tumor. Some
in the strict sense of Burnet (1970) has limited validity of the antigens identified have resulted from tumor-spe-
(but see below), cells of the immune system play impor- cific mutations, and some are even likely to be related
tant roles in tumor biology that have nothing to do with to the transforming event within the tumor cell (WoÈ lfel
et al., 1995). The surprise so far has been that the major-
ity of the antigens identified in human tumors have been* E-mail: js150x@nih.gov.
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unmutated differentiation antigens inappropriately ex- other molecules) transfected into tumor cells can lead
to killing of tumors formed by the parental tumor-cellpressed or overexpressed in the tumor. The era of total
line and can do so through a variety of mechanisms,genome sequencing is likely to have great influence
which are generally more dependent on granulocyteson future searches for antigenic tumor peptides. The
and cytokines than lymphocytes (Musiani et al., 1997).National Cancer Institute has initiated the Cancer Ge-
nome Anatomy Project with the goal of characterizing
State of the Field: Clinical Impactall of the genes expressed in several types of cancer
Immunotherapy has not yet become a force in cancercells (see http://www.ncbi.nlm.nih.gov/ncicgap). This
treatment, but when a broad view is taken of immune-will ultimately provide the information necessary in a
based therapy, the impact has been more significantsearch for potential antigens unbiased by the T cell
than is widely appreciated. Some of the impact comesresponse in individual patients.
from unexpected areas. For example, monoclonal anti-The identification of T cell±defined tumor antigens has
bodies (MAbs), given up for dead as therapeutic agentsbeen critical to the development of the field, but there
by most immunologists years ago, have staged a quietis no certainty that it has direct application to therapy
comeback. An anti-CD20 MAb has been shown to pro-(Boon and Old, 1997). The methods used produce little
duce meaningful, if not curative, clinical responses inor no evidence that the antigens found can function as
many B cell lymphoma patients who have failed chemo-tumor-rejection antigens. Moreover, the need to isolate
therapy (Maloney et al., 1997). The treatment is nontoxicand culture TILs provides the opportunity to introduce
and has been approved by the FDA. Radiolabeled formsartifacts into the system that further reduce the direct
of anti-CD20 in development are more toxic but alsorelevance of antigen identification (Faure et al., 1998).
more active. They have demonstrated potentially cura-Nevertheless, many studies are underway to determine
tive effects (Kaminski et al., 1996; Liu and Press, 1997)whether antigens identified by these methods can serve
and may soon be approved for clinical use as well. A 7as the basis for immunotherapy. Some investigators fa-
year follow-up of MAb 17±1A in Dukes' stage C colo-vor shared antigens because success with a single anti-
rectal cancer provides convincing evidence for a 32%gen would be applicable to many patients. The challenge
reduction in mortality in an adjuvant setting (RiethmuÈ llerhere is to show that shared antigens, which are most
et al., 1998). An antibody to HER2/neu was recentlycommonly unmutated differentiation antigens, can not
approved by the FDA for use in breast cancer patients.
only be recognized by patient T cells, but can mediate
Antibody engineering promises significant improve-
tumor rejection. Others favor unique, mutated antigens
ments in these results.
because of concerns about tolerance to self-antigens There are several other areas in which immune-based
and/or concern about inducing autoimmunity. A chal- therapy have been effective. In bone marrow trans-
lenge here is to demonstrate that unique tumor antigens plantation, the graft-versus-leukemia effect is a major
in humans have not induced peripheral tolerance. There factor for diseases like chronic myelogenous leukemia
has always been a concern that successful cancer ther- (CML), and its mechanism has been well characterized
apy would induce autoimmunity with unacceptable im- (Barrett, 1997). Donor-lymphocyte transfusions have
munopathology, although this has been notably absent proved useful to treat relapsed CML and some other
in virtually every study designed to look for it (Hara et hematological malignancies (Kolb and Holler, 1997). The
al., 1995; Vierboom et al., 1997). Until strikingly positive cytokines interleukin 2 (IL-2) and IFNa-2b have FDA ap-
clinical results are obtained in humans, all tumor anti- proval for specialized applications, despite severe toxic-
gens remain potential but unproven targets for therapy. ities. Most antigen-specific vaccine trials are not yet
Studies in mice have established useful principles of complete but some (e.g., a peptide-based MAGE-3 vac-
tumor immunotherapy. On the cautionary side, they show cine) have shown measurable activity (Marchand et al.,
that current methods have very limited applicability to 1995). Vaccination against the idiotype in patients with
large, disseminated, and/or well-established tumors and B cell lymphoma has a significant effect, although the
that the tumor-bearing state is hostile to active immuno- magnitude of the effect and the cost prevent broad ap-
therapy (discussed below). On the more positive side, plication (Hsu et al., 1997). Adoptive T cell therapy has
mouse studies show no single obvious, insurmountable dramatic effects in individual patients. The therapy of
barrier to turning the level of antigenicity displayed by choice for some bladder cancers is BCG (Ratliff, 1992).
tumors into effective immunogenicity. This provides a These results represent significant progress in cancer
rational basis for exploring the possibility of cancer im- treatment, where advances are typically incremental.
munotherapy. Careful studies have generally shown that
even ªnonimmunogenicº tumors can stimulate primary Current Research Emphasis
cytotoxic T lymphocyte (CTL) responses under carefully The realities today in tumor immunology are that tumor
controlled conditions (Liu et al., 1996). Tumors can be cells are normally poor immunogens and that immuno-
eradicated in mice by passive administration of CTL therapy often fails, even when a potent immune re-
(Vierboom et al., 1997) or antibody (Hara et al., 1995), sponse is present. Thus, there are two critical questions
even when the target antigens are expressed by normal that are driving research. First, what properties of the
cells. Individual T cell clones can mediate effective anti- immune system are responsible for the poor immunoge-
cancer responses, which indicates that tumor heteroge- nicity, and how can immunogenicity be increased? For
neity is not a consistently fatal limitation (Cheever and this purpose, the fact that the immunogen is a trans-
Chen, 1997). Active immunization can be effective, even formed cell is irrelevant. Second, what special proper-
when expression as a self-antigen limits the response ties of cancer cells and the tumor-bearing state present
tumor-related barriers to immunotherapy (Figure 1)?to low-avidity CTL (Morgan et al., 1998). Cytokines (and
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Figure 1. Simplified Scheme Depicting Some
of the Critical Points at which an Effective
Antitumor Immune Response Can Be Lost
(1) Tumor±stromal and tumor±endothelial in-
teractions can influence the visibility of the
tumor to the immune system.
(2) Tumor antigens may be inefficiently pre-
sented to the immune system.
(3) The tumor site may lack the prerequisites
to generate active professional APCs.
(4) Tumor antigens may not reach activated
APCs in a form that can be processed and
presented.
(5) Tumor-reactive T cells may not reach the
site of APCs presenting tumor antigens or
may be defective in their response to APCs.
(6) Tumor cells or cytokines derived from tu-
mor or stromal cells may prevent activation
of T cells via anergy induction or other mech-
anisms.
(7) Activated T cells may not recognize tumor
cells because of poor expression of MHC,
TAP, or other necessary molecules.
(8) Some tumors might kill activated T cells
through a Fas±FasL interaction.
(9) Granulocytes and macrophages may not
be activated to participate in tumor de-
bulking.
To answer the first question, attention is currently results have been obtained in mice (although rarely with
established tumors), careful analysis of the effects ob-focused on antigen presentation. Most tumors are not
antigen-presenting cells (APCs), so tumor antigens must served has returned the focus to professional APCs.
Studies showed that even tumor cells expressing highnormally be routed to professional APCs if they are to
stimulate an immune response. While it is possible that levels of an appropriate class I restricting element and
a costimulatory molecule are largely dependent on pro-some tumor antigens are intrinsically too weak to induce
an effective immune response, current evidence sug- fessional APCs for recognition (Huang et al., 1996), al-
though exceptions exist (Armstrong et al., 1998; Maricgests that this is not the limiting factor. Antigens known
to induce potent immune responses under the appro- et al., 1998). Intensive efforts are underway to determine
whether dendritic cells presenting tumor-derived anti-priate conditions often fail to mediate tumor eradication
(Speiser et al., 1997; Wick et al., 1997). So what is it genic peptides can induce an effective antitumor re-
sponse (Schuler and Steinman, 1997). The complexitiesabout tumor cells that make them such poor vehicles
for induction of immune responses? The answer may of phenotypic heterogeneity and variations in activation
state in dendritic cells will make a thorough investigationstart with the fact that tumor cells are largely recognized
as self. Even many of the antigens on tumor cells that can of this area a long-term undertaking (Banchereau and
Steinman, 1998).be recognized by T cells are unmutated differentiation
antigens, and foreign antigens expressed on tumor cells Some antigenic tumors appear virtually invisible to
the immune system. They induce no response and aresometimes elicit tolerance (Staveley-O'Carroll et al.,
1998). Thus, some have viewed immunotherapy as an not cleared by immune cells introduced by other means
(Melero et al., 1997; Speiser et al., 1997; Wick et al.,exercise in the controlled induction of autoimmunity
(Nanda and Sercarz, 1995; Speiser and Ohashi, 1998). 1997). This immunological ignorance can often be ame-
liorated by costimulation, suggesting that antigen pre-This requires substantial changes in the mode of presen-
tation to the immune system. sentation is again a key step. Other tumors can induce
antigen-specific T cell anergy, and this can be a veryIn the past few years, many attempts to induce im-
mune responses to tumors have involved creation of early event (Staveley-O'Carroll et al., 1998). The simple
concept that anergy is induced by encounter with a cellgene-modified tumor cells that would bypass the need
for T cell help or professional APCs, with the hope that expressing antigen in the absence of costimulation has
given way to more complex schemes, in part due to thethe response stimulated would kill both the transfected
cells and the untransfected parental tumor. Tumor cells demonstration that at least some tolerance induction
requires professional APCs (Adler et al., 1998). This fur-have been transfected with cytokines, initially with the
goal of eliminating the need for T cell help or altering the ther emphasizes the need for a detailed understanding
of the interaction of tumor cells with APCs. In view of theTh1/Th2 cytokine balance (Musiani et al., 1997; Clerici
et al., 1998). Transfection with costimulatory molecules finding that fibroblasts can be efficient APCs in lymphoid
organs (KuÈ ndig et al., 1995), this understanding mustattempted to make tumor cells into direct antigen-pre-
senting cells (Chen et al., 1992). While some positive take into account the point of encounter between tumor
Immunity
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cells and APCs. Many tumors metastasize to lymph barrier to immunotherapy. Tumors make other cyto-
kines, especially TGFb, that are strongly immunosup-nodes, indicating that localization to lymphoid organs
pressive; they can also have an altered susceptibilitydoes not in itself confer effective immunogenicity. But
to immunologic effector mechanisms (Chouaib et al.,there is very little information overall as to whether tumor
1997). There has been a great deal of interest recentlycells or tumor antigens are present or recognized in
in the possibility that tumors might create a zone oflymphoid organs.
immune privilege by expressing the Fas ligand (FasL)The danger model of immunity (Matzinger, 1994) has
and killing Fas-positive T cells or inducing FasL in thebeen referred to often in tumor immunology in recent
T cells, leading to fratricide (Hahne et al., 1996). On theyears, because in its most general sense it summarizes
other hand, FasL expression can lead to a substantialwhat is often observed in immune responses to tumors
inflammatory reaction. Gene transfer of FasL into a Fas-(Fuchs and Matzinger, 1996; Fenton and Longo, 1997).
negative tumor cell line induced tumor regression medi-There clearly needs to be some sort of inflammatory
ated by granulocytes (Arai et al., 1997). Thus, all that ismilieu to induce effective antitumor immunity. A detailed
certain to date is that T cells in cancer patients cananalysis of the heterogeneous processes induced by
show high levels of apoptosis and that the involvementcytokine-transfected tumor cells, which can often lead
of Fas is a complex issue (Green and Ware, 1997;to rejection of the untransfected tumor, showed that the
Reichert et al., 1998).initial release of cytokine usually triggered an inflamma-
During the course of tumor growth, many authors havetory reaction (Colombo and Forni, 1997). This was fol-
noted specific abnormalities in host T cells that makelowed by an influx of granulocytes. The cytokine and
them poorly responsive to normal activating stimuligranulocytes were responsible for the debulking phase
(Miescher et al., 1986). This phenomenon received in-of the tumor rejection. Some aspect of the occurrence
creased attention with the observation that the T cellof this rejection process then induced a specific antitu-
functional deficits were correlated with an apparent lossmor T cell response, which completed the rejection and
of several signal-transduction molecules, especially theproduced a state of long-lived tumor immunity. Suc-
TCRz chain and p56lck (Mizoguchi et al., 1992). It wascessful immunotherapy in many cases seems to be re-
later shown in one murine system that the majority ofduced to the problem of creating the right inflammatory
the reduction in TCRz and part of the reduction in p56lckreaction. Unfortunately, defining the elements of inflam-
was due to degradation of these molecules during pro-mation critical for the induction of tumor immunity and
tein extraction (Franco et al., 1995). This finding, alongmaking them effective has been difficult. Some tumors
with other concerns, prompted a cautionary commen-spontaneously induce inflammation, but that is not nec-
tary on the significance of the earlier observationsessarily indicative of a good prognosis. Intratumoral in-
(Levey and Srivastava, 1996), which, in turn, led to anjection of nonspecific inflammatory inducers like BCG
unfortunate misperception that observations of molecu-can sometimes suppress tumor growth, but it has not
lar alterations in T cells were all artifactual. However,proven clinically useful, except in bladder cancer. It is
the artifact was found to be limited to cell surface mole-likely that what is needed will vary from tumor to tumor,
cules in mouse spleen (Franco et al., 1995) and did notdepending on the intrinsic strength of the tumor anti-
extend to observed abnormalities of NF-kB in mousegens, the APCs present at the tumor site, and the
spleen or TCRz in the peripheral blood of humans withinvolvement of tumor-specific factors. Giving molecular
cancer. Nontheless, careful quantitative studies weredefinition to the widely accepted but hazy concept that
required to establish the validity of molecular and func-an inflammatory environment is required for induction
tional T cell abnormalities in the tumor-bearing stateand persistence of an antitumor reaction is a major goal
(Levey and Srivastava, 1996). Recent publications have
of tumor immunology.
solidified the observations of specific T cell abnormali-
Even if the inherent properties of the normal immune
ties in cancer and provided data that they correlate
system that make tumor cells generally nonimmuno-
in several cases with clinical status. Current studies
genic are identified and circumvented, the tumor itself continue to focus most often on the level of TCRz and
may still present additional obstacles to effective immu- impaired NF-kB activation (Correa et al., 1997; Ling et
notherapy. Genomic instability is a property of tumor al., 1998). These changes appear more often in some
cells, and this facilitates loss of specific gene expres- cancer types than others. The mechanism of the TCRz
sion. In the effector phase of an antitumor response changes observable by Western blotting or flow cytome-
directed against a single antigen, the loss of expression try is unclear, but there is emerging evidence that the
of antigen, a necessary major histocompatibility com- presence of these changes may be a marker for patients
plex (MHC) restricting element, or the transporter asso- with poor prognosis and poor potential response to im-
ciated with antigen processing (TAP) could be critical. munotherapy. At least in renal cell cancer, the alterations
All of these losses do occur in tumors (Uyttenhove et in NF-kB activation appear to be due to products se-
al., 1983; Garrido et al., 1997; Seliger et al., 1997). Poor creted by the tumor (Kolenko et al., 1997). Although
presentation of tumor antigens can also be due to cyto- these changes appear to be more frequent late in the
kine effects. Tumor lines expressing IL-10 have sharply course of the disease, for some tumors they can be
reduced levels of MHC and TAP (Petersson et al., 1998). present at the stage of carcinoma in situ (Nieland et al.,
There are no compelling data as yet to indicate whether 1998). Affected T cells generally recover their functional
loss of antigen-presenting ability is due to immune se- properties when removed from the tumor-bearing envi-
lection or has an effect on the course of the disease. It ronment, suggesting that methods may be developed
to reverse the functional deficits in vivo. Because of theis not known whether it constitutes a major practical
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heterogeneous and generally relatively late appearance al., 1998). In T cell±based therapy, the unique capabili-
ties of both active immunization and adoptive T cellof these changes, they are probably not primary factors
in tumor development, but they may constitute a signifi- approaches deserve attention (Yee et al., 1997). How-
ever, the potential for inducing a tumor-specific re-cant barrier to therapy in cancer patients that exhibit
them. It is critical to establish the specific mechanisms sponse that accelerates tumor growth rather than re-
tarding it needs to be kept in mind (Toes et al., 1996).responsible for the observed molecular changes, to de-
termine whether the changes are responsible for the Tumor immunology has two experimental limitations
that deserve more attention. First, available mouse mod-functional defects or merely useful markers of defects
in certain cancers, and to see whether treatments aimed els are of limited value. Mouse models in general use
remain useful for testing basic concepts, particularlyat normalizing T cells improve patient responsiveness
to immune-based therapy. with the availability of genetically manipulated strains.
However, the transplantable tumor lines used have oftenThe final tumor-induced factor that may influence
therapy involves alterations in tumor vasculature and been in culture too long and grow too fast to be useful
models for the human condition. Injection of transplant-tumor±stromal interactions. Lymphocyte access to the
tumor bed depends on extravasation mediated by a able tumor cells also does not permit study of tumor±
host interactions during malignant transformation andseries of adhesion molecules. Endothelial cell ligands
for L-selectin and a4b7 integrin were shown not to be early tumor development. While these limitations are
widely known and acknowledged, they have yet to in-expressed in nonimmunogenic tumors of mice trans-
genic for the SV40 T antigen under the control of the spire any significant new approaches. Improved mouse
models would permit new types of study and help toinsulin promoter (Onrust et al., 1996). Tumor±stromal
effects are complex. The rejection of an immunogenic bridge the gap to clinical application. Second, human
clinical experimentation needs to be streamlined. TheUV-induced tumor was shown to depend on the pres-
ence and the genetics of the stromal cells (Singh et al., combination of large tumor burdens and poor immune
function makes patients with advanced cancer poor pre-1992). Injection of small fragments of solid tumor con-
taining stromal cells often led to progressive tumor dictors of clinical response. Efficient strategies to reach
the point of testing in early cancer, the adjuvant setting,growth, while injection of a much larger number of tu-
mor cells as a suspension produced rejection. Stromal and even prophylaxis are needed.
The biggest scientific questions in tumor immunologyeffects may be involved in other observations. It has
been noted repeatedly that in mice injected with tumor are the same as those in other areas of immunology. To
answer these questions, tumor immunology needs tocells, a wide variety of immune-based treatments are
effective if begun before the tumor is firmly established. remain informed by what is current in basic immunology
as well as results from the clinic. In turn, it will continueThe probability of success drops rapidly, reaching es-
sentially zero around 4 weeks after injection. The effect to serve as a proving ground for concepts in basic immu-
nology.is not due to tumor burden, because at 4 weeks in many
experiments only microscopic deposits of tumor are
detectable. Teasing out the factors involved in such References
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